Rapid Novor is a biotech company located at Accelerator Centre’s Advanced Manufacturing and Hardware Innovation Lab.

The company is dedicated to developing the next generation of protein sequencing technology. The team is comprised of an interdisciplinary team of highly accomplished bioinformaticians, mass spectrometry scientists and experienced entrepreneurs. Together, they are passionate about advancing technology and offering top-notch services to speed up antibody related discoveries.

What Is De Novo Sequencing?

In mass spectronomy (mass spectrum measures the masses within a sample), de novo peptide sequencing is the method in which a peptide amino acid sequence is determined from tandem mass spectrometry.

Rapid Novor has created a technology platform called REmAb™, which provides a direct and independent insight into your antibody sample. The team has created a process that made it possible to sequence any given antibody proteins routinely. There are several potential reasons a customer may need their service or want to use this technology:

  1. In some patent application or cases, the customer wants to be absolutely sure about the antibody sequence. In this situation, they may already obtained the sequences through DNA sequencing. Our service can serve as an orthogonal method to confirm the sequence.
  2. For antibodies that were originally generated decades ago, the original cell line may be dead/changed, or simply not accessible. In this situation, our technology is the only way to rescue the exact same antibody if the customer still have some of the antibody proteins left.
  3. Biosimilar development. We can help sequence or confirm the protein sequences of those off-patent drugs.

Changing the Industry

For over a decade people have had the impression that de novo peptide sequencing with mass spectronomy is slow. However, Dr. Ma, as a bioinformatician who worked on this problem for years, wanted to make a change. Since January 2015, Dr. Ma devoted himself to a new de novo sequencing tool, Novor. The outcome of this dedication caused impressive results: Novor achieved a speed of 300 spectra per second (with a MacBook Pro laptop computer), with accuracy better than other available tools to date.

With a speed surpassing all modern mass spectrometers and software solutions in the market, the software may enable applications that were previously not possible.

The company’s REmAb™ platform is built upon this core algorithm and has helped over a hundred customers worldwide in their antibody research and development.

The Team

Rapid Novor began with three founders,  Bin Ma, President and Chief Scientist, Mingjie Xie, CEO and Qixin Liu, CTO.  Since then, the company has grown with a team armed with the expertise, experience and passion dedicated to advancing life-science for better human health with the next generation of protein sequencing.

In January of 2016, the company entered the Accelerator Programs and were able leverage the mentorship available in order to build out their company faster. In the AC’s Hardware Innovation Lab space, they have their own state-of-the-art lab, meaning they can do everything  internally and speed up the sequencing process and get results even faster. There new found success also allowed them grow their team – hiring a full-time developer and sales representatives to help scale the business.

What’s Next?

Xie, CEO shares,

“All of the clients so far have been very happy with the results and we know that the work we are doing can be instrumental to the future of healthcare. We are noticing however, that we need to put more energy into educating the market, because what we do is very complex in nature but we want to make it so that everyone understands the benefits of what we do and what we can do for them. Over the last two years we’ve been leaning heavily on marketing. Our goal for 2018 is to continue that but use an approach of educating in a non-intimidating manor.”

Rapid Novor is also looking to grow the team in the areas of research & development and sales and marketing for 2018.

To learn more about Rapid Novor, please visit RapidNovor.com